Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist.
Wong
P C
PC
Du Pont Merck Pharmaceutical Company, Wilmington, DE 19880-0400.
Tam
S W
SW
Herblin
W F
WF
Timmermans
P B
PB
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects; D007093:Imidazoles / Q000378:metabolism / Q000494:pharmacology*; D066298:In Vitro Techniques; D007700:Kinetics; D019808:Losartan; D009119:Muscle Contraction / Q000187:drug effects; D051381:Rats; D011945:Receptors, Angiotensin / Q000187:drug effects* / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism; D013777:Tetrazoles / Q000378:metabolism / Q000494:pharmacology*
D057911:Angiotensin Receptor Antagonists; D007093:Imidazoles; D011945:Receptors, Angiotensin; D011956:Receptors, Cell Surface; D013777:Tetrazoles; D000804:Angiotensin II; D019808:Losartan